Roche says that the FDA has delayed final approval of Mircera, a new anemia drug. Roche is staying mum about exactly what questions the FDA wants answered before approval, but a company spokesman says that the agency won't approve any new anemia drugs until it has a chance to review the class of drugs aimed at treating anemia in kidney patients. Mircera is intended to compete with Aranesp and Epogen, which have come under intense scrutiny recently. Report